|   From the Trenches

Better Living Through T-cells

Every week it feels like there’s yet another big event happening in the engineered T-cell therapy space. Recently it’s been biotech-pharma partnering. Before that it was the biggest biotech IPO of the year. And before that, it was a parade of positive clinical data at ASH. It’s as relentless as the blizzards pummeling Boston this winter. As CEO of Unum Therapeutics, a next-generation T-cell therapy company, I find myself sitting in the middle of the action and so I thought that it might be a good topic to talk about for my first “From the trenches” contribution.

This blog was written by Chuck Wilson, CEO of Unum Therapeutics, as part of the “From the Trenches” feature of LifeSciVC.

Read more.


  |   In the News

Biotech M&A by Slow Simmer: An Inside Look at the Build to Buy Deal

Here’s a question for consideration: What does it mean to acquire a virtual, single asset biotech that was ‘built’ for the sole purpose of being bought? The answer is much more complex than you might think.

Read more.


  |   LifeSciVC

Data Snapshot: Dwarfed By Big Pharma, Biotech By The Numbers

By Bruce Booth, DPhil, Partner

Biotech fills the news these days – whether it’s the announcement of exciting new clinical data, another high-flying IPO, or a big M&A deal. Amidst the significant “share of voice” in the coverage of young and emerging biotech in the media, it’s easy to forget the relative scale of the sector relative to larger BioPharma companies.

Read more.


  |   From the Trenches

Learnings From a Reluctant Entrepreneur

I am a scientist by vocation and training and an entrepreneur by accident.  I got into the business of starting companies when I decided almost a decade ago that I wanted to work on a new crazy therapeutic modality and the only way to do it, and innovate, was by starting from scratch; roll up your sleeves, license the IP, get VC money, build a team, and go for it.  Luckily, when I co-founded my first startup company, I did not know anything about the process, so no pre-conceived biases informed by experience, sort of like skydiving and having absolute confidence your parachute will open, right? Nine years later, in my second company, I’ve learned some valuable lessons…

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. 

Read more.


  |   LifeSciVC

Where Does All That Biotech Venture Capital Go?

By Bruce Booth, DPhil, Partner

Venture capital investing in biotech has long been hard to disaggregate: how much goes to “early stage” vs “late stage”, how much goes to CNS vs oncology, discovery vs Phase 3, etc…

Today BIO’s David Thomas and Chad Wessel have put some much-needed light onto the biotech investor trends over the past decade with a newly released report.

Read more.